| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcellx, Inc. | Director | Common Stock | 2.1M | $116M | $55.27 | Feb 8, 2022 | Indirect |
| Protagonist Therapeutics, Inc | Director | Stock Option (right to buy) | 25.7K | Jan 2, 2024 | Direct | ||
| Neoleukin Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25K | May 11, 2021 | Direct | ||
| Arcellx, Inc. | Director | Series B-1 Preferred Stock | 0 | Feb 8, 2022 | Indirect | ||
| Arcellx, Inc. | Director | Series B-2 Preferred Stock | 0 | Feb 8, 2022 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | Jan 2, 2024 | 1 | $0 | 4 | Jan 4, 2024 | Director |
| PTGX | Protagonist Therapeutics, Inc | Jan 16, 2023 | 1 | $0 | 4 | Jan 18, 2023 | Director |
| PTGX | Protagonist Therapeutics, Inc | May 26, 2022 | 1 | $0 | 4 | May 27, 2022 | Director |
| ACLX | Arcellx, Inc. | Feb 8, 2022 | 3 | $0 | 4 | Feb 9, 2022 | Director |
| ACLX | Arcellx, Inc. | Feb 3, 2022 | 0 | $0 | 3 | Feb 3, 2022 | Director |
| PTGX | Protagonist Therapeutics, Inc | May 27, 2021 | 1 | $0 | 4 | May 28, 2021 | Director |
| NLTX | Neoleukin Therapeutics, Inc. | May 11, 2021 | 1 | $0 | 4 | May 13, 2021 | Director |